{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:40:53Z","timestamp":1790498453786,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>Does the presence of single nucleotide polymorphisms (SNPs) in the FSH receptor gene (FSHR) and\/or FSH beta subunit-encoding gene (FSHB) influence ovarian response in predicted normal responders treated with rFSH?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>The presence of FSHR SNPs (rs6165, rs6166, rs1394205) has a statistically significant impact in ovarian response, although this effect is of minimal clinical relevance in predicted normal responders treated with a fixed dose of 150\u2009IU rFSH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Ovarian reserve markers have been a breakthrough in response prediction following ovarian stimulation. However, a significant percentage of patients show a disproportionate lower ovarian response, as compared with their actual ovarian reserve. Studies on pharmacogenetics have demonstrated a relationship between FSHR or FSHB genotyping and drug response, suggesting a potential effect of individual genetic variability on ovarian stimulation. However, evidence from these studies is inconsistent, due to the inclusion of patients with variable ovarian reserve, use of different starting gonadotropin doses, and allowance for dose adjustments during treatment. This highlights the necessity of a well-controlled prospective study in a homogenous population treated with the same fixed protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>We conducted a multicenter multinational prospective study, including 368 patients from Vietnam, Belgium, and Spain (168 from Europe and 200 from Asia), from November 2016 until June 2019. All patients underwent ovarian stimulation followed by oocyte retrieval in an antagonist protocol with a fixed daily dose of 150\u2009IU rFSH until triggering. Blood sampling and DNA extraction was performed prior to oocyte retrieval, followed by genotyping of four SNPs from FSHR (rs6165, rs6166, rs1394205) and FSHB (rs10835638).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Eligible were predicted normal responder women &amp;lt;38\u2009years old undergoing their first or second ovarian stimulation cycle. Laboratory staff and clinicians were blinded to the clinical results and genotyping, respectively. The prevalence of hypo-responders, the number of oocytes retrieved, the follicular output rate (FORT), and the follicle to oocyte index (FOI) were compared between different FSHR and FSHB SNPs genotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>The prevalence of derived allele homozygous SNPs in the FSHR was rs6166 (genotype G\/G) 15.8%, rs6165 (genotype G\/G) 34.8%, and rs1394205 (genotype A\/A) 14.1%, with significant differences between Caucasian and Asian women (P\u2009&amp;lt;\u20090.001). FSHB variant rs10835638 (c.-211 G&amp;gt;T) was very rare (0.5%). Genetic model analysis revealed that the presence of the G allele in FSHR variant rs6166 resulted in less oocytes retrieved when compared to the AA genotype (13.54\u2009\u00b1\u20090.46 vs 14.81\u2009\u00b1\u20090.61, estimated mean difference (EMD) \u22121.47 (95% CI \u22122.82 to \u22120.11)). In FSHR variant rs1394205, a significantly lower number of oocytes was retrieved in patients with an A allele when compared to G\/G (13.33\u2009\u00b1\u20090.41 vs 15.06\u2009\u00b1\u20090.68, EMD \u22121.69 (95% CI \u22123.06 to \u22120.31)). A significantly higher prevalence of hypo-responders was found in patients with the genotype A\/G for FSHR variant rs6166 (55.9%, n\u2009=\u200957) when compared to A\/A (28.4%, n\u2009=\u200929), ORadj 1.87 (95% CI 1.08\u20133.24). No significant differences were found regarding the FORT across the genotypes for FSHR variants rs6166, rs6165, or rs1394205. Regarding the FOI, the presence of the G allele for FSHR variant rs6166 resulted in a lower FOI when compared to the A\/A genotype, EMD \u221213.47 (95% CI \u221222.69 to \u22124.24). Regarding FSHR variant rs6165, a lower FOI was reported for genotype A\/G (79.75\u2009\u00b1\u20093.35) when compared to genotype A\/A (92.08\u2009\u00b1\u20096.23), EMD \u221213.81 (95% CI \u221225.41 to \u22122.21).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>The study was performed in relatively young women with normal ovarian reserve to eliminate biases related to age-related fertility decline; thus, caution is needed when extrapolating results to older populations. In addition, no analysis was performed for FSHB variant rs10835638 due to the very low prevalence of the genotype T\/T (n\u2009=\u20092).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>Based on our results, genotyping FSHR SNPs rs6165, rs6166, rs1394205, and FSHB SNP rs10835638 prior to initiating an ovarian stimulation with rFSH in predicted normal responders should not be recommended, taking into account the minimal clinical impact of such information in this population. Future research may focus on other populations and other genes related to folliculogenesis or steroidogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>This study was supported by an unrestricted grant by Merck Sharp &amp; Dohme (MSD). N.P.P. reports grants and\/or personal fees from MSD, Merck Serono, Roche Diagnostics, Ferring International, Besins Healthcare, Gedeon Richter, Theramex, and Institut Biochimique SA (IBSA). N.L.V. and M.T.H. report consultancy and conference fees from Merck, Ferring, and MSD, outside the submitted work. P.D. has received honoraria for lecturing and\/or research grants from MSD, Ferring International, and Merck. D.S. reports grants and\/or personal fees from MSD, Ferring International, Merck Serono, Cook, and Gedeon Richter. A.R.N., B.A.M., C.S., J.M., L.H.L., P.Q.M.M., H.T., and S.G. report no conflict of interests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>NCT03007043<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deab068","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T18:10:24Z","timestamp":1618423824000},"page":"1711-1721","source":"Crossref","is-referenced-by-count":43,"title":["The effect of polymorphisms in\n                    <i>FSHR<\/i>\n                    and\n                    <i>FSHB<\/i>\n                    genes on ovarian response: a prospective multicenter multinational study in Europe and Asia"],"prefix":"10.1093","volume":"36","author":[{"given":"Nikolaos P","family":"Polyzos","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Medicine, Dexeus University Hospital, Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, Ghent University (UZ Gent), Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-5736","authenticated-orcid":false,"given":"A R","family":"Neves","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Medicine, Dexeus University Hospital, Barcelona, Spain"},{"name":"Autonomous University of Barcelona, Cerdanyola del Vall\u00e8s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-785X","authenticated-orcid":false,"given":"P","family":"Drakopoulos","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium"},{"name":"Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Spits","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Alvaro Mercadal","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Gynecology Department, Barcelona, Spain"},{"name":"Fundaci\u00f3 Puigvert, Reproductive Medicine Department, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Reproductive Medicine, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Q M","family":"Ma","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-170X","authenticated-orcid":false,"given":"L H","family":"Le","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Ho","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mertens","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Stoop","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University (UZ Gent), Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Tournaye","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium"},{"name":"Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium"},{"name":"Department of Obstetrics, Gynecology, Perinatology and Reproduction, Institute of Professional Education, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-6912","authenticated-orcid":false,"given":"N L","family":"Vuong","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"2021070807483097700_deab068-B1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.fertnstert.2007.11.093","article-title":"Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women","volume":"91","author":"Achrekar","year":"2009","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2018.00589","article-title":"De. Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the follicle-to-oocyte (FOI) index","volume":"9","author":"Alviggi","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807483097700_deab068-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmy019","article-title":"Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: A systematic review and meta-analysis","volume":"24","author":"Alviggi","year":"2018","journal-title":"Hum Reprod Update"},{"key":"2021070807483097700_deab068-B4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0895-4356(03)00011-8","article-title":"Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology","volume":"56","author":"Attia","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"2021070807483097700_deab068-B5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/humupd\/dmu020","article-title":"Anti-m\u00fcllerian hormone: ovarian reserve testing and its potential clinical implications","volume":"20","author":"Broer","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2021070807483097700_deab068-B6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/humupd\/dmq034","article-title":"AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis","volume":"17","author":"Broer","year":"2011","journal-title":"Hum Reprod Update"},{"key":"2021070807483097700_deab068-B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Hum Reprod Update"},{"key":"2021070807483097700_deab068-B8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4939-0659-8_4","article-title":"Gene polymorphisms in female reproduction","volume":"1154","author":"Casarini","year":"2014","journal-title":"Methods Mol Biol"},{"key":"2021070807483097700_deab068-B9","first-page":"370","article-title":"Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?","volume":"31","author":"Drakopoulos","year":"2016","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2018.00461","article-title":"Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON criteria-the why","volume":"9","author":"Esteves","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807483097700_deab068-B11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/humrep\/deq361","article-title":"Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation","volume":"26","author":"Genro","year":"2011","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.rbmo.2019.05.018","article-title":"The relationship between FSH receptor polymorphism status and IVF cycle outcome: a retrospective observational study","volume":"39","author":"K\u00f6nig","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2021070807483097700_deab068-B13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.fertnstert.2013.01.086","article-title":"Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization","volume":"99","author":"La Marca","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2021070807483097700_deab068-B15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/humrep\/dez299","article-title":"The effect of type of oral contraceptive pill and duration of use on fresh and cumulative live birth rates in IVF\/ICSI cycles","volume":"35","author":"Montoya-Botero","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.fertnstert.2012.11.051","article-title":"Biomarkers of ovarian response: current and future applications","volume":"99","author":"Nelson","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B17","first-page":"3365","article-title":"Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype","volume":"85","author":"Perez Mayorga","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070807483097700_deab068-B18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.fertnstert.2018.04.039","article-title":"Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including \u223c15,000 women","volume":"110","author":"Polyzos","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/humrep\/deaa183","article-title":"SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same","volume":"35","author":"Polyzos","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.fertnstert.2013.03.031","article-title":"Does the time interval between antim\u00fcllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist?","volume":"100","author":"Polyzos","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.rbmo.2012.01.024","article-title":"Anti-m\u00fcllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors","volume":"24","author":"Polyzos","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2021070807483097700_deab068-B22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/humrep\/dev149","article-title":"Sub-optimal responders following controlled ovarian stimulation: An overlooked group?","volume":"30","author":"Polyzos","year":"2015","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.fertnstert.2013.04.029","article-title":"Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization\/intracytoplasmic sperm injection","volume":"100","author":"Polyzos","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B24","volume-title":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"2021070807483097700_deab068-B25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40265-020-01324-w","article-title":"Current therapeutic options for controlled ovarian stimulation in assisted reproductive technology","volume":"80","author":"Racca","year":"2020","journal-title":"Drugs"},{"key":"2021070807483097700_deab068-B26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.fertnstert.2020.04.004","article-title":"Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes","volume":"114","author":"Schirmer","year":"2020","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B27","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1210\/jc.2012-2780","article-title":"Effects of the FSHB-subunit promoter polymorphism -211G-T on the Hypothalamic-pituitary-ovarian axis in normally cycling women indicate a gender- specific regulation of gonadotropin secretion","volume":"98","author":"Schuring","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070807483097700_deab068-B28","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1530\/EJE-13-0624","article-title":"Mechanisms in endocrinology: genetics of FSH action: a 2014-and-beyond view","volume":"170","author":"Simoni","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2021070807483097700_deab068-B29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.fertnstert.2019.05.017","article-title":"Sequence variants in FSHR and CYP19A1 genes and the ovarian response to controlled ovarian stimulation","volume":"112","author":"Song","year":"2019","journal-title":"Fertil Steril"},{"key":"2021070807483097700_deab068-B30","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s10815-015-0600-5","article-title":"Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies","volume":"32","author":"Tang","year":"2015","journal-title":"J Assist Reprod Genet"},{"key":"2021070807483097700_deab068-B32","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod"},{"key":"2021070807483097700_deab068-B33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/sim.2010","article-title":"A method for meta-analysis of molecular association studies","volume":"24","author":"Thakkinstian","year":"2005","journal-title":"Stat Med"},{"key":"2021070807483097700_deab068-B34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/gtmb.2018.0182","article-title":"Effects of a polymorphism in the promoter region of the follicle-stimulating hormone subunit beta (FSHB) gene on female reproductive outcomes","volume":"23","author":"Trevisan","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"2021070807483097700_deab068-B35","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1159\/000366356","article-title":"Ala307Thr and Asn680Ser polymorphisms of FSHR gene in human reproduction outcomes","volume":"34","author":"Trevisan","year":"2014","journal-title":"Cell Physiol Biochem"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/6\/1711\/37948217\/deab068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/6\/1711\/37948217\/deab068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T11:19:16Z","timestamp":1625743156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/6\/1711\/6247313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,23]]},"published-print":{"date-parts":[[2021,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab068","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,4,23]]}}}